| Literature DB >> 27226721 |
Jonathan Bergman1, Aaron A Laviana2.
Abstract
Palliative care involves aggressively addressing and treating psychosocial, spiritual, religious, and family concerns, as well as considering the overall psychosocial structures supporting a patient. The concept of integrated palliative care removes the either/or decision a patient needs to make: they need not decide if they want either aggressive chemotherapy from their oncologist or symptom-guided palliative care but rather they can be comanaged by several clinicians, including a palliative care clinician, to maximize the benefit to them. One common misconception about palliative care, and supportive care in general, is that it amounts to "doing nothing" or "giving up" on aggressive treatments for patients. Rather, palliative care involves very aggressive care, targeted at patient symptoms, quality-of-life, psychosocial needs, family needs, and others. Integrating palliative care into the care plan for individuals with advanced diseases does not necessarily imply that a patient must forego other treatment options, including those aimed at a cure, prolonging of life, or palliation. Implementing interventions to understand patient preferences and to ensure those preferences are addressed, including preferences related to palliative and supportive care, is vital in improving the patient-centeredness and value of surgical care. Given our aging population and the disproportionate cost of end-of-life care, this holds great hope in bending the cost curve of health care spending, ensuring patient-centeredness, and improving quality and value of care. Level 1 evidence supports this model, and it has been achieved in several settings; the next necessary step is to disseminate such models more broadly.Entities:
Keywords: end of life; integrated; palliative care; urology
Year: 2016 PMID: 27226721 PMCID: PMC4863682 DOI: 10.2147/JMDH.S90822
Source DB: PubMed Journal: J Multidiscip Healthc ISSN: 1178-2390
Treatment options to be considered by men with castrate-resistant prostate cancer
| Treatment | Side effects | Quality of life benefit | Average survival benefit | Yearly cost (USD) | Logistic burden |
|---|---|---|---|---|---|
| Abiraterone | Fluid retention, hypertension, hypokalemia | Delays progression of pain and QOL deterioration if taken with prednisone | 4 months | $60,000 | Daily oral |
| Sipuleucel-T | Dizziness, arthralgia | None | 4 months | $93,000 | Biweekly infusion after leukopheresis |
| Enzalutamide | Seizures, hallucinations | Improved QOL when administered after docetaxel | 2–5 months | $90,000 | Daily oral |
| Radium 223 | Myelosuppression, diarrhea | None | 3–4 months | $70,000 | Monthly infusion |
| Docetaxel (first-line chemo) | Hair loss, neuropathy | Improved QOL, reduced pain | 3–4 months | $15,000 | Every 3-week hourly infusion |
| Cabazitaxel (second-line chemo) | Neutropenia, hypersensitivity | Unknown | 3 months | $45,000 | Every 3-week hourly infusion |
| Cabozantinib | Fatigue, hypertension, hand-foot-mouth disease | Decreased bone pain | Unknown | $120,000 | Daily oral |
| Palliative care | None | Unstudied in this population | Unstudied in this population; 3 months in individuals with metastatic lung cancer | Variable | Variable |
Abbreviation: QOL, quality of life.
Androgen deprivation options for men with castrate-resistant prostate cancer
| Method of androgen deprivation | Unique benefits | Unique side effects | Yearly cost | Logistic burden |
|---|---|---|---|---|
| Surgical castration | Avoidance of ongoing interventions | Surgical morbidity | $4,000 (once) | One-time surgical procedure |
| Leuprolide | Lowest cost of injectables | Injection site pain | $2,400 | Every 3 months subcutaneous |
| Leuprolide long acting | Least frequent dosing | Injection site pain, irreversible for 6 months | $6,000 | Every 6 months subcutaneous |
| Bicalutamide | Reversible if side effects not tolerated | Less effective as monotherapy than other castration options | $365 | Daily oral |
| Degarelix | Castration achieved by day 3 (7–14 days with leuprolide) | Cardiac arrhythmias | $6,000 | Monthly subcutaneous |